BSX · NYSE
Medical Devices · United States
Snapshot 2026-11-11 · Latest financial period 2026-09-30 · Yahoo Finance. Quotes may be delayed; reporting periods can differ.
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Company websiteQ3 2026
Published 2026-10-28
Q3 2026 REPORT HIGHLIGHTS
A cyber-disrupted quarter, a lower share count and a pending acquisition make cash recovery more important than the headline earnings multiple.
Sales and EPS beat the cited provider snapshot, but Q4 guidance still implies declining revenue.
Gross margin fell 321 basis points; adjusted operating margin fell 147 basis points.
At the prior denominator, adjusted income implies about $0.711 per share versus reported $0.73.
June cash and debt are dated proxies; September cash flow is unknown.
Penumbra funding, dilution and integration require a separate future model; no unearned synergies enter this standalone value.
Comparable businesses
Same business group first, then company size. Preferred market cap: 0.5–2x; extended range: one-third–3x. Outside that range, industry benchmarks are labeled separately and excluded from peer medians.
No suitable peers with fresh, comparable size data are available. We have not substituted unrelated companies.
| Metric | BSXBoston Scientific CorporationSnapshot 2026-11-11Financial period: 2026-09-30 |
|---|---|
| Market capMarket value, converted to USD | US$65.41B |
| Forward P/EProvider forward earnings estimate | 14.42x |
| EV / EBITDAEnterprise value / trailing EBITDA | 13.71x |
| Revenue growthLatest quarter vs prior-year quarter | 1.4% |
| Operating marginLatest reported quarter | 19.6% |
| Free cash flow yieldTrailing cash flow / market cap | 3.8% |
| Net debt / EBITDANet debt / trailing EBITDA | 2.04x |
| Debt / equityTotal debt / positive book equity | 0.46x |
| Trailing P/ETrailing twelve-month earnings | 19.04x |
| Price / bookPrice / positive book equity per share | 2.55x |
| EV / salesEnterprise value / trailing revenue | 3.62x |
| Earnings growthLatest quarter vs prior-year quarter | -21.5% |
| Gross marginTrailing twelve months | 68.0% |
| Net marginTrailing twelve months | 16.6% |
| Return on equityProvider trailing return; positive equity only | 14.1% |
| Free cash flow marginTrailing free cash flow / revenue | 11.8% |
| Dividend yieldIndicated annual dividend / price | — |
| Earnings payoutProvider trailing dividend payout | 0.0% |
| Current ratioCurrent assets / current liabilities | 1.36x |
| BetaProvider historical market sensitivity | 0.58 |
Reviewed operating groups override broad sector classifications. Other companies are matched only within a sufficiently specific provider industry. Business mix, geography and accounting standards can still differ. Market caps are converted to USD using exchange rates captured during the snapshot refresh. Financial ratios that would mix currencies are omitted. Snapshots must be at most 14 days old and no more than seven days apart for automatic selection.
Peer medians require at least two valid similar-size peers for each metric. Negative earnings, nonpositive equity, missing data and irrelevant bank ratios are not presented as attractive valuations. A higher or lower number is not automatically a better investment. Financial statement periods are not calendar-aligned across companies.
Reported performance
Periods are grouped by their ending calendar year or quarter, not identical fiscal calendars. Exact period-end dates appear in tooltips and reported figures. When reporting currencies differ and a recent captured FX rate is available, money and EPS are normalized to USD for comparison. This is not a historical FX restatement. Gaps are not estimated.
Financial statements load separately from the research page.
Source: . Window ends at the latest available reporting period.
Standalone charts use the stated reporting currency. When a chart comparison spans currencies, money and EPS can be normalized to USD using a recent captured FX snapshot; this is for comparison only, not a historical FX restatement. Stock-based compensation is noncash. Free cash flow is operating cash flow less capital spending, which may include capitalized software. Missing metrics are not estimated or assumed to be zero. Banking and insurance ratios require industry-specific interpretation. Latest restatements may differ from figures in older episodes.
Market context
Price history loads separately.
Illustrative price = your earnings-per-share assumption × your P/E assumption. This is not a price target or a complete valuation model.
Starting assumptions, when available, use provider forward estimates as of 2026-11-11. Negative earnings require a different valuation method. This calculation omits balance-sheet, dilution and execution risks.
THE RESEARCH RECORD
FREE RESEARCH PACKET · Q3 2026
A cyber-disrupted quarter, a lower share count and a pending acquisition make cash recovery more important than the headline earnings multiple.
Research published October 28, 2026 · Download original report
Read Research PacketPresentation · 2026-10-28 · YouTube
Presentation · 2026-07-31 · YouTube
Presentation · 2026-04-23 · YouTube
Verify material figures against company filings. Market data and AI-assisted analysis may contain errors.
